New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
16:13 EDTTGTXTG Therapeutics reports Q2 EPS (36c), consensus (24c)
Reports Q2 license revenue $38,095, consensus $40,000.
News For TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
08:37 EDTTGTXTG Therapeutics enters into global collaboration with Checkpoint Therapeutics
TG Therapeutics (TGTX) announced an agreement with Checkpoint Therapeutics, a newly formed subsidiary of Coronado Biosciences (CNDO), to develop and commercialize Checkpoint's fully human anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. Checkpoint will develop and commercialize these antibodies in solid tumors. The antibodies were generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDs at Dana-Farber Cancer Institute. Both programs are currently in pre-clinical development and are anticipated to enter the clinic in 2016. Under the terms of the agreement, TG Therapeutics will make an up-front payment as well as make development and sales-based milestone payments and will pay a tiered single digit royalty on net sales.
08:36 EDTTGTXCoronado forms new subsidiary to develop novel immuno-oncology antibodies
Subscribe for More Information
February 19, 2015
09:05 EDTTGTXTG Therapeutics management to meet with Brean Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use